FAQs and Guidances

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Federal government:

Professional societies:

  • American Society of Clinical Oncology FAQ: Emerging issues and challenges in caring for patients with cancer during the coronavirus pandemic

  • American Association for Cancer Research FAQ: Information on virtual annual meetings

  • American Cancer Society FAQ: Common questions about the new coronavirus outbreak

  • Society for Immunotherapy of Cancer Resources: Patient management and basic and translational research

  • Community Oncology Alliance resources: Coronavirus (COVID-19) practice resources and protocols

  • Leukemia & Lymphoma Society FAQ: Resources and what you should know about the coronavirus

  • American Society for Radiation Oncology FAQ: COVID-19 recommendations and information

  • American College of Surgeons resources: For the surgical community

  • Society for Immunotherapy of Cancer resources: Implications for patients, translational research

  • GO2 Foundation for Lung Cancer resources

  • American Society for Transplantation and Cellular Therapy resources

  • European Blood and Marrow Transplantation Society recommendations

  • World Marrow Donor Association resources

  • National Institute for Health Care Management Foundation resources

Research centers:

  • St. Jude Children’s Research Hospital FAQ: COVID-19 and children with cancer

  • Journal of the National Comprehensive Cancer Network: How to manage cancer care during COVID-19 pandemic

Companies:

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login